Oncolytics Biotech completes US$3.7M offering of units

Date Closed

August 16, 2019

Lead Office

Calgary

Value

3.70 Million USD

On August 16, 2019, Oncolytics Biotech completed its previously announced public offering of 4,619,773 units at a price of US$0.71 per unit for gross proceeds of approximately US$3.7 million. Oncolytics plans to use the net proceeds of the offering for research and development activities and working capital purposes.

Oncolytics is a biotechnology company with offices in Calgary and San Diego. Its focus is the development of pelareorep, an immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies.

McCarthy Tétrault LLP advised Oncolytics with a team led by Michael Bennett that included Robert Nearing and Steve Marshall (Tax).

People